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Objectives:This study aimed to examineprognosis and causes of death in hemodialysis
(HD) patients with critical limb ischemia (CLI) after endovascular therapy (EVT).
Background: EVT is becoming a first-line treatment in patients with CLI. Nonetheless,
only a few studies have examined prognosis and its predictors in HD patients with CLI
undergoing EVT, who are known to be at high-risk. Moreover, causes of death in this
population are not clarified to date.
Methods: We examined 175 consecutive patients who underwent EVT for CLI
between March 2009 and March 2014.
Results: Among these, 126 patients were dependent on HD and their 2-year all-cause
death and 2-year major amputation rates were 28% and 14%, respectively. Cox
proportional hazards analyses revealed that lower body mass index (hazard ratio
[HR] = 0.89, 95% confidence interval [CI] = 0.82-0.98, P = 0.03) and prior stroke
(HR = 2.34, 95%CI = 1.10-4.85, P = 0.03) were independent predictors of all-cause
death, and lower serum albumin (HR = 0.44, 95%CI = 0.22-0.92, P = 0.03) along with
currently smoking (HR = 4.73, 95%CI = 1.43-14.1, P = 0.01) were independent
predictors of major amputation in HD patients. The leading cause of death in this
population was infections, most of which were lower extremity infections.
Conclusions: The incidences of all-cause death and major amputation seemed
acceptable in HD patients undergoing EVT for CLI. In this high-risk subset,
management of infection might be a potential therapeutic target.
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1 | INTRODUCTION
Peripheral arterial disease (PAD) is defined as atherosclerotic occlusive
disease of the lower extremities and is characterized by multiple
atherosclerosis risk factors. The increased risk of cardiovascular events in
PAD is related to the severity of thedisease.1Critical limb ischemia (CLI) is a
severe clinical presentation of PAD that manifests as lower extremity
ischemic restpainor ischemic skin lesions leading toulcerationorgangrene.
Patients with CLI often have multiple medical comorbidities. Dominguez
etal reporteda1-yearmortality rateof25%anda1-yearamputationrateof
25% in this high-risk subset.2 A recent report showed that the independent
predictors of mortality in patients with CLI were hemodialysis, older age,
lower body mass index (BMI), non-ambulatory status, cerebrovascular
disease, lower left ventricular ejection fraction, andRutherfordclass5or6.3
Historically, bypass surgery has been the gold standard for
revascularization in CLI patients because of complex culprit lesion
characteristics, such as heavy calcification and chronic total occlusion.
However, a rapid evolution of endovascular therapy (EVT) is changing
the treatment paradigm for CLI patients, and EVT is becoming a
common first-line treatment.4–6
374 | © 2017, Wiley Periodicals, Inc. wileyonlinelibrary.com/journal/joic J Interven Cardiol. 2017;30:374–381.
In recent years, the number of hemodialysis (HD) patients with CLI
has been increasing.6–8 Surgical approaches are believed to present
higher risks for HD patients because of the presence of critical
comorbidities.4,7,9,10 Patients with CLI need a diversified approach for
management, such as aggressive medical therapies, wound care, and
revascularization with an emphasis on limb salvage.
In terms of HD patients undergoing percutaneous coronary
intervention, several reports have already revealed that HD patients
have a poorer prognosis than non-HD patients.11,12 However, only a
few studies to date have examined the clinical outcomes in HD
patients with CLI who undergo EVT, and compared the prognosis as
well as its predictors between HD and non-HD patients.13,14 In
addition, causes of death in HD patients after EVT for CLI are not
clarified in detail, although cardiovascular death is believed to be
the leading cause.15 The main purposes of this study were (1) to
examine the prognosis and its predictors after EVT in HD patients with
CLI and (2) to investigate causes of death in this high-risk subset. A
comparison with respect to prognosis, its predictors, and causes of
death was simultaneously made between HD and non-HD patients.
2 | METHODS
2.1 | Study design and population
This was a retrospective, non-randomized, single arm, and single
center study. The cases of 181 consecutive patients who underwent
EVT for CLI betweenMarch 2009 andMarch 2014 at TokyoWomen’s
Medical University Hospital were retrospectively reviewed. Among
these patients, 6 who were lost to follow-up within 6 months were
excluded. The medical records of the remaining 175 consecutive
patientswere examined.Of the 175 patients, 126 consecutive patients
were dependent on hemodialysis (Fig. 1).We compared the incidences
of adverse events in HD versus non-HD patients. Subsequently, we
analyzed predictors of adverse events in the group of patients who
received HD. Data collection was based on electronic medical records
and angiographic records. Medical history, atherosclerosis risk factors,
laboratory test results, and other data were obtained from pre-
procedure clinical notes, admissions histories, and inpatient documen-
tation. Medications at discharge were also assessed, along with lesions
treated and procedural characteristics. CLI was defined as presenta-
tion with lower extremity ischemic rest pain, ulceration, or gangrene
(Rutherford classes 4-6) with confirmation of poor blood flowdetected
by angiographic evaluation. The clinical indication for endovascular
revascularization in patients with CLI was resting pain or non-healing
wound. The treatment strategies for EVT were left to the discretion of
attending operators. Patients treated with stents were prescribed two
doses of aspirin (100mg/day), cilostazol (100-200mg/day),
or clopidogrel (75mg/day). Patients treated with balloon angioplasty
alone were prescribed at least one of the three medications above.
Antiplatelet therapy was started at least 1 week before EVT.
After stent implantation, dual antiplatelet therapy was continued
for at least 6 months, and subsequently, one of the antiplatelet agents
was discontinued according to the discretion of attending operators.
Technical success was angiographically defined as dilatation of all
critical inflow lesions or establishment of continuous inline flow from
at least one below-knee (BK) artery to the ankle in BK lesion.
2.2 | Endpoints
The primary endpoint in this studywas all-cause death and the following
parameters were also evaluated: (1) major amputation, (2) re-interven-
tion, and (3) cause of death. All-cause deaths were confirmed by direct
record documentation. Major amputation was defined as major lower
extremity limb amputation above the level of the ankle joint. Re-
intervention consisted of both major and minor re-interventions. Major
re-intervention included bypass grafting, jump grafting, and interposition
graft revision, as well as thrombectomy and thrombolysis for stents with
loss of patency. Minor re-intervention was defined as percutaneous
transluminal angioplasty and/or stenting.16 Cardiovascular death was
defined as death in the presence of acute coronary syndrome, fatal
cardiac arrhythmia, or refractory heart failure. Infection was defined as
any localizationwith clinical evidenceof infection and/or positiveculture.
2.3 | Follow-up
The median follow-up period was 21 months (interquartile range
13-35) in this study. After discharge, patients visited the outpatient
clinic routinely every 1-3months. Six patients whowere lost to follow-
upwithin 6monthswere excluded. Re-intervention,major amputation,
and death and its cause were confirmed by reviewing medical records.
Re-intervention was clinically driven due to the recurrence of resting
pain, ulceration, or gangrene. No re-intervention due to abnormal non-
invasive testing was included.
2.4 | Statistical analysis
Categorical variables were compared using the χ2 test. Continuous
variables were compared using Student’s t-test or the Mann-
Whitney U-test, depending on their distributions. In the results,
continuous variables are expressed as the mean value ± standard
deviation. Event-free survival curves were constructed using the
Kaplan-Meier method and compared using the log-rank test. Cox
proportional hazards regression models were used to estimate
FIGURE 1 Between March 2009 and March 2014, 181
consecutive patients who underwent endovascular therapy (EVT)
for critical limb ischemia (CLI) at Tokyo Women’s Medical University
Hospital were retrospectively reviewed. Of these patients, 6 were
lost to follow-up within 6 months and were excluded. Of the
remaining 175 patients, 126 were dependent on hemodialysis (HD),
whereas 49 were not
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hazard ratios of all-cause mortality, major amputation, and re-
intervention. Each covariate was included in the multivariate
analysis if it though to be clinically important or its P-value was
less than 0.1 in the univariate analysis. Finally, for the entire study
population, BMI, DM, stroke, CAD, CKD over 3, HD, low EF, prior
CABG, and BNP were included in the analysis of all-cause death,
and current smoking status and the value of albumin on admission
were included in the analysis of major amputation. For HD
patients, BMI, prior stroke, BNP, isolated above knee lesion, and
bilateral lesion were included in the analysis of all-cause death,
and current smoking status, dyslipidemia, and the value of albumin
on admission were included in the analysis of major amputation.
Also for non-HD patients, BMI, hemoglobin, and DM were
included in the analysis of all-cause death (Supplemental Tables
S2-S6). For all tests, a two-sided P-value of less than 0.05 was
considered statistically significant. The statistical analysis was
performed using JMP Pro® 12 software (SAS Institute Inc., Cary,
NC, USA).
2.5 | Ethical considerations
The study protocol followed the regulations of the hospital’s ethics
committee. All participating patients provided written informed
consent at the time of EVT to perform proposed treatment and
follow-up evaluation. Patient enrollment was carried out according to
the principles stated in the Declaration of Helsinki.
3 | RESULTS
The baseline clinical backgrounds of patients are summarized in
Table 1. There were no significant differences between HD and
non-HD patients except for the prevalence of diabetes. Patients
who underwent peritoneal dialysis were not included in this study.
The medications provided at discharge are presented in Table 2.
There were no significant differences between HD and non-HD
patients except for the frequencies of aspirin and clopidogrel
prescriptions. In terms of lesions treated and procedural
TABLE 1 Baseline characteristics
Characteristics All patients (n = 175) HD (n = 126) Non-HD (n = 49) P-value
Age, year old 67.7 ± 9.6 67.3 ± 9.3 68.8 ± 10.5 0.36
Male gender 133 (76) 96 (76) 37 (76) 0.92
Body mass index, kg/m2 22.5 ± 3.8 22.4 ± 3.8 22.8 ± 3.7 0.54
Diabetes mellitus 59 (34) 48 (38) 11 (22) 0.05
Hypertension 145 (83) 102 (81) 43 (88) 0.28
Dyslipidemia 80 (46) 52 (41) 28 (57) 0.06
Hyperuricemia 27 (15) 18 (14) 9 (18) 0.50
Family history of IHD 28 (16) 20 (16) 8 (15) 0.94
Prior stroke 46 (26) 35 (28) 11 (22) 0.47
Smoking 94 (54) 63 (51) 31 (63) 0.11
Current smoking 16 (9) 11 (9) 5 (10) 0.76
Coronary artery disease 99 (57) 73 (58) 26 (53) 0.56
CKD overG3 137 (78) 126 (100) 11 (22) <0.01
Renal transplantation 12 (7) 7 (6) 5 (10) 0.27
Atrial fibrillation 41 (23) 34 (27) 7 (14) 0.08
Low LVEF (<35%) 39 (22) 29 (23) 10 (20) 0.71
Prior CABG 35 (20) 26 (21) 9 (18) 0.74
Prior PCI 57 (33) 44 (35) 13 (27) 0.29
Prior PPI 44 (25) 30 (24) 14 (29) 0.51
Laboratory data
Albumin, g/dL 3.5 ± 0.5 3.5 ± 0.6 3.4 ± 0.7 0.33
Hemoglobin, g/dL 11.0 ± 1.8 11.1 ± 1.7 11.0 ± 2.0 0.74
BNP, pg/mL 830 ± 1108 860 ± 1114 743 ± 961 0.53
C-reactive protein, mg/dL 3.6 ± 5.0 3.7 ± 5.1 3.3 ± 5.0 0.64
Uric acid, mg/dL 5.3 ± 1.3 5.3 ± 1.3 5.5 ± 1.4 0.19
HbA1c, % 6.4 ± 1.3 6.4 ± 1.4 6.3 ± 0.9 0.61
BNP, brain natriuretic peptide; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; IHD, ischemic heart disease; LVEF, left ventricular
ejection fraction; PCI, percutaneous coronary intervention; PPI, percutaneous peripheral intervention.
Categoric data are presented as number (%) and continuous data as mean ± standard deviation or median (interquartile range).
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characteristics, there were no significant differences between HD
and non-HD patients except for the prevalence of aorto-iliac and
bilateral lesions (Table 3).
During the follow-up period (median, 21months), the incidence of
2-year all-cause death rate was 28% in HD patients and 11% in non-
HD patients (P = 0.0098, Fig. 2A). Although the 2-year cardiovascular
death ratewas similar between the groups (8%vs 2%, P = 0.31, Fig. 2B),
HD patients had a higher risk of death by infections than the non-HD
patients at 2-years (16% vs 4%, P = 0.030, Fig. 2C). Major amputation
rates at 2-years were 14% in HD patients and 5% in non-HD patients
(P = 0.38, Fig. 3A). Re-intervention rates at 2-years were 34% in HD
patients and 15% in non-HD patients (P = 0.036, Fig. 3B).
The results of multivariate analyses for all-cause death and
major amputation in HD patients are shown in Table 4. Cox
proportional hazards regression analyses revealed that lower body
mass index (hazard ratio [HR] = 0.89, 95% confidence interval
[CI] = 0.82-0.98, P = 0.03) and prior stroke (HR = 2.34, 95%
CI = 1.10-4.85, P = 0.03) were independent predictors of all-cause
death; lower serum albumin (HR = 0.44, 95%CI = 0.22-0.92,
P = 0.03) and currently smoking (HR = 4.73, 95%CI = 1.43-14.1,
P = 0.01) were independent predictors of major amputation; and
there were no independent predictors of re-intervention. The
results of uni- and multivariate analyses for all-cause death in non-
HD patients are shown in Supplemental Table S1. Hemoglobin
TABLE 2 Medication at discharge
Characteristics All patients (n = 175) HD (n = 126) Non-HD (n = 49) P-value
Angiotensin-converting enzyme inhibitor 15 (9) 10 (8) 5 (10) 0.63
Angiotensin receptor blocker 81 (46) 56 (44) 25 (51) 0.62
Calcium channel blocker 74 (42) 54 (43) 20 (41) 0.81
Aspirin 113 (65) 87 (69) 26 (53) 0.05
Clopidogrel 63 (36) 51 (40) 12 (24) 0.05
Cilostazol 35 (20) 28 (22) 7 (14) 0.14
Eicosapentaenoic acid 49 (28) 35 (28) 14 (30) 0.79
Nitrate 43 (25) 33 (26) 10 (21) 0.44
Statin 56 (32) 39 (31) 17 (13) 0.63
Βeta blocker 64 (37) 43 (34) 21 (43) 0.28
Diuretics 35 (20) 22 (17) 13 (27) 0.18
Categoric data are presented as number (%).
TABLE 3 Lesion and procedural characteristics
Characteristics All patients (n = 175) HD (n = 126) Non-HD (n = 49) P-value
Rutherford class
4 34 (19) 24 (19) 10 (20)
5 121 (69) 86 (68) 35 (71) 0.69
6 20 (11) 16 (13) 4 (8)
Wound infection 43 (25) 35 (28) 8 (16) 0.11
Treated lesion
Aorta-iliac 23 (13) 20 (16) 3 (6) 0.09
Femoral-popliteal 98 (56) 70 (56) 28 (57) 0.85
Below the knee 117 (67) 85 (67) 32 (65) 0.28
Stent usage 65 (37) 49 (39) 16 (33) 0.44
Isolated below the knee 65 (37) 44 (35) 21 (43) 0.33
Isolated above the knee 58 (33) 41 (33) 17 (35) 0.71
Bilateral lesions 9 (5) 9 (7) 0 (0) 0.05
TASC category
B 28 (16) 23 (18) 5 (10)
C 109 (62) 75 (60) 34 (70) 0.36
D 38 (22) 28 (22) 10 (20)
Categoric data are presented as number (%).
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(HR = 0.46, 95%CI = 0.20-0.80, P = 0.02) was the independent
predictor of all-cause death. There were no independent predictors
of major amputation and re-intervention in this group. The results
of uni- and multivariate analyses for all-cause death and major
amputation in non-HD and HD patients are shown in Table 5. Forty
(31.7%) HD patients died during the follow-up period. Their causes
of death are shown in Fig. 4. The leading cause of death was
infections (21 of 40 patients; 52.5%), most of which were lower
FIGURE 2 Kaplan-Meier estimates of (A) all-cause death, (B) cardiovascular death, and (C) death from infection in hemodialysis (HD) and
non-HD patients. (A) The Kaplan-Meier curve shows the incidence of all-cause death at 2 years. The median duration of follow-up was
21 months and the incidence of all-cause death at 2 years was 28% in HD patients and 10% in non-HD patients (P = 0.0098). (B) The Kaplan-
Meier curve shows the incidence of cardiovascular death at 2-years, which was 7% in HD patients and 2% in non-HD patients. There were no
statistically significant differences between HD and non-HD patients (P = 0.31). (C) The Kaplan-Meier curve shows the incidence of death
from infection at 2-years, which was 15% in hemodialysis (HD) patients and 4% in non-HD patients (P = 0.03)
FIGURE 3 Kaplan-Meier estimates of (A) major amputation and (B) re-intervention in hemodialysis (HD) and non-HD patients. (A) The
Kaplan-Meier curve shows rates of major amputation at 2-years, which were 14% in HD patients and 5% in non-HD patients. There were no
statistically significant differences between HD and non-HD patients (P = 0.38). (B) The Kaplan-Meier curve shows rates of re-intervention at
2-years, which were 34% in HD patients and 15% in non-HD patients (P = 0.036)
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extremity infections (17 of 21 patients; 81.0%). Eleven (22.4%)
non-HD patients died, and their causes of death are shown in
Supplemental Fig. S1. The leading cause of death was cardiovas-
cular death (4 of 11 patients; 36.4%).
4 | DISCUSSION
The present study had three primary findings. First, in contemporary
practice, HD patients with CLI had a survival rate of 72% and an
amputation-free survival rate of 86% at 2-years post-EVT. Second, in
HD patients, lower BMI and prior stroke were independent predictors
for all-cause death, and lower serum albumin along with currently
smoking were independent predictors for major amputation. Third,
infection was the leading cause of death in HD patients with CLI
undergoing EVT, and most of the infections that led to death were
lower extremity infections.
4.1 | All-cause death
Consistentwith a previous report,3 the present study revealed that HD
patients with CLI after EVT showed a worse prognosis compared to
non-HD patients. In general, HD patients have higher risks of both
cardiovascular death and infection,17 which result in a worse
prognosis. In this study, 1- and 2-year all-cause death rates in HD
patients were 15% and 28%, respectively. These results are a slightly
better than those of a previous report by Suematsu et al in which the
incidence of all-cause death in HD patients with CLI due to isolated
below-the-knee disease was 25% at 1 year after EVT.13,18 Bypass
surgery is often considered for the treatment of CLI in the case of
complex culprit lesion characteristics, such as severe calcification or
chronic total occlusion. However, HD patients with CLI generally have
multiple systemic comorbidities, which leads to a hesitation to perform
bypass surgery. The CRITISCH registry revealed that CLI patients who
underwent bypass surgery were at a higher risk of in-hospital death
TABLE 5 Uni- and multivariate analysis of predictors in HD and non-HD patients
Univariate Multivariate
Predictors Crude odds ratio 95%CI P-value Adjusted odds ratio 95%CI P-value
All cause death
BMI 0.90 (0.83-0.97) 0.01 0.89 (0.81-0.97) <0.01
BNP 1.00 (0.99-1.00) <0.01 1.00 (0.99-1.00) 0.03
Prior CABG 1.60 (0.83-2.90) 0.07 1.20 (0.56-2.42) 0.63
DM 1.64 (0.93-2.84) 0.08 1.21 (0.59-2.44) 0.60
HD 2.25 (1.17-4.72) 0.01 1.75 (0.42-5.12) 0.40
CKD over 3 3.04 (1.46-7.21) 0.01 4.36 (0.84-19.46) 0.07
Major amputation
Albumin 0.60 (0.34-1.11) 0.10 0.59 (0.32-1.11) 0.10
Smoking 2.85 (1.03-10.02) 0.02 1.76 (0.53-6.75) 0.36
Current smoking 5.70 (2.20-14.10) <0.01 4.74 (1.70-13.54) <0.01
There were no independent predictors of reintervention.
TABLE 4 Uni- and multivariate analysis of predictors in HD patients
Univariate Multivariate
Predictors Crude odds ratio 95%CI P-value Adjusted odds ratio 95%CI P-value
All cause death
BMI 0.92 (0.84-0.97) 0.04 0.89 (0.82-0.98) 0.03
BNP 1.00 (0.99-1.00) 0.02 1.00 (0.99-1.00) 0.06
Prior stroke 1.97 (1.02-3.71) 0.04 2.34 (1.10-4.85) 0.03
Isolated above the knee lesion 0.51 (0.22-1.07) 0.08 0.44 (0.16-1.01) 0.06
Bilateral lesions 2.05 (1.00-3.68) 0.05 1.32 (0.30-4.01) 0.68
Major amputation
Albumin 0.47 (0.24-0.94) 0.03 0.44 (0.22-0.92) 0.03
Dyslipidemia 2.62 (0.90-8.53) 0.07 2.86 (0.97-9.55) 0.06
Current smoking 4.83 (1.48-14.10) 0.01 4.73 (1.43-14.10) 0.01
There were no independent predictors of reintervention.
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than those who underwent EVT.19 According to a previous report,20
amputation free survival and overall survival were similar for EVT and
bypass surgery as first-line revascularization therapy in non-HD
patients with CLI. Furthermore, a recent publication that focused on
HD patients with CLI showed that clinical outcomes such as overall
survival or major amputation after EVT or bypass surgery were not
significantly different.21 Therefore, the less invasive EVT might be
acceptable for the first-line treatment of CLI in HD patients, although
such patients have complex culprit lesions.
4.2 | Major amputation
In this study, the amputation rates in HDpatients at 1 and 2 years were
6% and 14%, respectively, and were not significantly different from
those of non-HD patients. In contrast, the re-intervention rate up to
2 years was significantly higher in HD patients than in non-HD
patients. A previous study on a large CLI registry in Japan reported
amputation rates of 26% and 36% at 1 and 2 years, respectively, in
patients who received infra-inguinal EVT for CLI.22 The better limb
salvage rate observed in our studymay be explained by the inclusion of
patients with aorto-iliac lesions (16%) or fewer patients of Rutherford
class 6 (13%). Our results also suggest that, although HD patients with
CLI needed revascularization more frequently, appropriate revascu-
larization in HD patients with CLI may facilitate achieving equivalent
outcomes to those of non-HD patients with CLI.
4.3 | Predictors for all-cause death and major
amputation
Prior stroke and lower BMI were independent predictors for all-cause
death in ourmultivariate analysis. These findings are consistentwith the
results of previous reports from a large PAD registry.3,18 We
also identified lower serum albumin and currently smoking as
independent predictors for major amputation. Hypoalbuminemia is
caused by a chronic inflammatory state or malnutrition. Serum albumin
<3 g/dL is strongly related to delayed wound healing, which results in
wound infection.23,24 The major amputation-free rate after EVT was
significantly lower in patients with wound infection than in those
without.22 Therefore, better management for wound infections may be
important for improving the limb salvage rate. Smoking promotes the
development of atherosclerosis via endothelial dysfunction, monocyte
recruitment, development of plaque, and thrombosis at damaged vessel
walls. Therefore, atherosclerosis intuitively appears to be an irreversible
state; nonetheless, a study by Armstrong et al revealed that smoking
cessation is efficacious in patients with symptomatic peripheral artery
disease and successful smoking cessation was associated with
significantly reduced mortality and improved amputation-free survival,
even in patients with CLI.25
4.4 | Causes of death
Cardiovascular death is known as a major cause of death, accounting
for over 50% of deaths in patients with PAD.1 HD patients had a
significantly higher rate of infectious death than non-HD patients.17
However, there is a paucity of studies that examined the causes of
death in HD patients with CLI undergoing EVT. Our study showed that
infection was the leading cause of death in this high-risk subset, and
lower extremity infections accounted for most of the deaths due to
infection. One notable result in this study was the relatively low
amputation rate (14% at 2 years) in HD patients. Accordingly, the
“failure to amputate phenomenon”was believed to be present. In other
words, a few patients could have undergone an amputation surgery
instead of refusing amputation at the expense of severe lower leg
infection with potentially fatal consequences. A possible explanation
for this result is that the phagocytic function of granulocytes may have
deteriorated in HD patients who had frequent and repetitive
exposures to potential infectious risk factors during regular dialysis
therapy.17 Since the incidence of cardiovascular death did not differ
significantly between HD and non-HD patients in the present study,
prevention of infection or an appropriate management of lower
extremity infections might be vital in HD patients with CLI.
4.5 | Limitations
The present study has several limitations. First, this was a retrospective,
non-randomized, single arm, andsingle center study. Second, the sample
size of patient cohort was small, and the study population included
Japanese patients only. Third, there are unique characteristics of our
institution that may prevent the generalizability of our findings. Our
hospital has an HD center, and cardiologists primarily perform EVT in
PADcases, ofwhich a fewundergo open surgery. Therefore, 72%of the
studypopulationwasdependentonHD, andmanypatientswithTASCC
(62%) and TASC D (22%) were treated by EVT. Fourth, quantitative
vascular analysis was not performed in this study. Finally, non-invasive
examinations to confirm flow, such as the ankle-brachial index (ABI) or
skin perfusion pressure (SPP), were not routinely performed in all
patients before and after intervention. Therefore, ABI or SPP were not
used to define CLI or the technical success of the intervention.
FIGURE 4 Causes of death in hemodialysis (HD) patients. The pie
chart displays the causes of death in HD patients, which were
cardiovascular death in 11 (27.5%), infection in 21 (52.5%),
pulmonary embolism in 1 (2.5%), and unknown in 7 (17.5%)
patients. The leading cause of death was infections, most of which
were lower extremity infections
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5 | CONCLUSION
In contemporary practice, 2-year all-cause death rate and 2-year major
amputation rate in HD patients undergoing EVT for CLI were 28% and
15%, which were significantly worse than those in non-HD patients.
The leading cause of death was infection, most commonly in the lower
limbs. Management of lower limb infection might be a potential
therapeutic approach in this high-risk subset.
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